DAX-044
IL-12 Avikine®
A next generation potency-optimised IL-12 cytokine-antibody fusion molecule. Engineered to deliver unprecedented therapeutic index for this class of drug.
PROGRESS: IND enabling
Learn MoreReshaping the future of immunotherapies
A unique Australian biotechnology company inventing targeted immunotherapies for oncology and autoimmune diseases.
Unbound by convention, we think differently when tackling the toughest diseases. Our breakthrough discoveries re-establish the scientific frontier, advance the field of medicine, and will improve lives around the world for generations to come.
With our completely unbiased approach we do away with assumptions and let biology be our guide. By exploring any target, in any cell type, across any disease, we are generating solutions to the most complex therapeutic problems for the benefit of all patients.
Our research is built on a deep understanding of the immune system. By performing every experiment with our own hands in our own labs, we feel what the biology is telling us. Layering in our proprietary technology stack, we are targeting previously unreachable domains.
We translate bold new concepts from our Avikine®, Immunoglue™ and high-dimensional biology research platforms into next generation immunotherapies. Our pipeline reflects our ability to solve historical development challenges and bring the most effective medicines to patients.
Our success is driven by our team, a group of people as unique and ambitious as it is highly aligned. Audax’s inimitable advantage comes from our collective intelligence and dedication.
A next generation potency-optimised IL-12 cytokine-antibody fusion molecule. Engineered to deliver unprecedented therapeutic index for this class of drug.
PROGRESS: IND enabling
Learn MoreA novel immunotherapy target that has immune and tumour cell intrinsic effects. Ablation of the DAX-037 target enhances the fitness and function of cytotoxic immune cells by sensitising these populations to endogenous IL-15.
PROGRESS: Lead Series
A series of novel Avikine® molecules tailored for use in oncology.
PROGRESS: Hit Generation
A series of novel Avikine® molecules tailored for use in autoimmune disease.
PROGRESS: Lead Series
A new molecular glue discovered using our high-throughput immunophenotype screening platform. Under development for use in autoimmune disease.
PROGRESS: Lead Series